The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases.

Novita I. Khairunnisa,Fumiyuki Yamasaki,Yoshihiro Miyata,Morihito Okada,Nobutaka Horie

Clinical Lung Cancer（2023）

引用 0|浏览1

暂无评分

摘要

•Lorlatinib-related hyperlipidemia can be statin-resistant, necessitating additional or alternative treatment to achieve cholesterol target levels.•PCSK9 inhibitors could be considered in patients who cannot achieve cholesterol target levels despite being treated with the maximum tolerated dose of statins.

查看译文

关键词

Non-Small Cell Lung Carcinoma,Dyslipidemia,Anaplastic lymphoma kinase,ALK inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要